During the initial inflammatory phase, MSCs also enhance survival, reduce pulmonary and intestinal inflammation, improve intestinal barrier function, and decrease intestinal recruitment of CD8+ T lymphocytes in ALI, regardless of antibiotic treatment (210, 211). This evidence concerns the gene CD8A and acute respiratory distress syndrome.